
RHAPSODY: Rilonacept, an IL-1α and IL-1β Trap, Resolves Pericarditis Episodes and Reduces Risk of Recurrence in a Phase 3 Trial of Patients with Recurrent Pericarditis


Allan Klein^{1*}, Massimo Imazio^{2*}, Paul Cremer¹, Antonio Brucato³, Antonio Brucato³, Antonio Brucato⁵, Alistair Wheeler¹², Liangxing Zou⁵, and John F. Paolini⁵, for the RHAPSODY Investigators


¹Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Biomedical and Clinical Science, University of Milan, Fatebenefratelli Hospital, Milan; ⁴Pauley Heart Center, Virginia Commonwealth University, Richmond; ⁵Kiniksa Pharmaceuticals Corp., Lexington, MA; ⁶Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome; ⁷Cardiology Unit, University of Vermont Medical Center, Burlington; ⁸Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center, Burlington; ⁸Cardiovascular Clinical Research Institute, Abbott Northwestern Hospital, Minneapolis; ¹⁰Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester; ¹¹Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash Centre, Victorian Heart Institute, Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash Cen

- treatment¹⁻³

recurrent pericarditis⁴⁻⁸







JACC; 9. Arcalyst [package insert]. Kiniksa Pharmaceuticals (UK), Ltd.; 2021

Presented by Randy Perrin, Kiniksa Pharmaceuticals Corp.

Definition of clinical response: weekly average daily pericarditis pain: <2.0 (11-point NRS); CRP level <0.5 mg/dL; on monotherapy of study drug without a recurrence

No or minimal pain is defined as non-missing daily NRS < 2. The percentage of days with no or minimal pain in the first 24, 16, and 8 weeks is calculated for each subject using 24x7, 16x7, 8x7, respectively, as the denominator. Missing values in pain diary will be counted as 0 day with no or minimal pain. On days of using ORT or corticosteroid, count as 0 day with no or minimal pain. If bailout rilonacept was used, each administration (loading dose or not) will be counted as

Rilonacept Was Well-tolerated With No Drug-related Serious Adverse Events

Category of Treatment-Emergent Adverse Events (TEAEs) ^{a,} n (%)	Run-In	Randomized Withdrawal		Overall Study
	Rilonacept (N = 86)	Rilonacept Before Bailout (N = 30)	Placebo Before Bailout (N = 31)	Rilonacept or Placebo (N = 86)
Any TEAE ^b	69 (80.2)	24 (80.0)	13 (41.9)	74 (86.0)
TEAE by maximum severity ^c				
Mild	52 (60.5)	16 (53.3)	9 (29.0)	47 (54.7)
Moderate	15 (17.4)	8 (26.7)	4 (12.9)	25 (29.1)
Severe	2 (2.3)	0	0	2 (2.3)
Drug related TEAE ^d	46 (53.5)	10 (33.3)	1 (3.2)	50 (58.1)
Serious TEAE	1 (1.2)	1 (3.3)	1 (3.2)	5 (5.8)
Drug related serious adverse event	0	0	0	0
TEAEs leading to dose interruption	0	1 (3.3)	0	1 (1.2)
TEAEs leading to study drug discontinuation	4 (4.7)	0	0	4 (4.7)
TEAEs leading to death	0	0	0	0
TEAEs of infection or infestation	14 (16.3)	12 (40.0)	3 (9.7)	29 (33.7)
TEAEs of upper respiratory tract infection	12 (14.0)	7 (23.3)	0	19 (22.1)
TEAEs of injection-site reaction	28 (32.6)	5 (16.7)	0	29 (33.7)

CONCLUSION: Rilonacept Resolved Acute Episodes and Reduced Risk of Pericarditis Recurrence

In patients with symptomatic recurrent pericarditis failing SoC, rilonacept (once-weekly IL-1α and IL-1β trap):


- **Recurrent pericarditis episodes resolved with addition of rilonacept**
- Rapid (after first dose) and sustained reductions in pain NRS and CRP
- Resolution of pericarditis manifestations, where present at baseline
- Primary Efficacy Endpoint: HR 0.04; p<0.0001

- Consistent results at randomized withdrawal Week 24

American College of Cardiology, Kentucky Chapter | Virtual | November 6, 2021

Proportion of Patients with Absent/Minimal Pericarditis Symptoms^b at Week 16

25% Placebo Rilonacept Data at Weeks 8 and 24 were consistent Percent of Days with No or Minimal Pain^c in First 16 Weeks



^aPatients with multiple events were counted once in the same category. ^bTEAEs: AEs that start or increase in severity; from first study drug dose to 6 weeks after last dose; ^cEach patient represented according to the maximum severity; ^dThese events were related, possibly related, or missing, as assessed by

- The only events in rilonacept arm (n=2) occurred during temporary drug interruptions of 1 and 3 weeks No recurrences during remainder of RW period in patients who received bailout rilonacept

Rilonacept supported steroid tapering/discontinuation and obviated initiation in colchicine resistant patients

- 49% of patients were on corticosteroids at baseline; 80% of patients were on colchicine at qualifying episode

Improvements in symptomatology maintained throughout the study while on treatment

- 81% of patients on rilonacept reported no/minimal pericarditis symptoms at RW Wk 16 versus 25% for

98% of trial days with none/minimal pain versus 45.9% for placebo (LS mean; p < 0.0001)